Aviceda Therapeutics
CAMBRIDGE, MA · Biotechnology, Other · 51 employees
Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly using a propriety HALOS platform Technology. Aviceda is developing glyco-immuno therapeutics targeting devastating ocular and systemic
Funding history
- Funding Round — $75.0M — Jan 2025
- Series series c — $207.5M — Jan 2025
- Funding Round — $18.9M — May 2024
- Funding Round — $15.6M — May 2023
- Funding Round — $75.0M — Mar 2022
Recent signals
- Apr 01, 2025: Aviceda Therapeutics Appoints Jeffrey Nau as Chief Executive Officer
- Jan 13, 2025: Raised $75.0M
- Jan 07, 2025: Raised $207.5M in Series series c
- May 31, 2024: Raised $18.9M
- May 19, 2023: Raised $15.6M
- Mar 28, 2022: Raised $75.0M
- Mar 28, 2022: Raised $8.4M
- Sep 16, 2020: Raised $4.3M in Series seed
See plans & pricing → Track Aviceda Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.